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OBJECTIVES: A medical food is formulated to be consumed or administered enterally 
under the supervision of a physician, and is intended for the speciﬁc dietary manage-
ment of a disease or condition for which distinctive nutritional requirements are 
established by medical evaluation. In the US, medical foods are a special product cat-
egory regulated by the FDA. In Europe, a similar category called “Foods for Special 
Medical Purposes” (FSMPs) is covered by the Foods for Particular Nutritional Uses 
directive and regulated by the European Commission (EC). Our objective is to review 
and compare the characteristics of, and regulatory environments for, medical foods 
and FSMPs. METHODS: We conducted internet and PubMed searches to identify 
information and guidance covering medical foods and FSMPs, including relevant FDA 
and EC regulations. We also reviewed and compared the characteristics, place in 
therapy, and potential economic impact of these products. RESULTS: Medical foods 
do not require pre-approval from the FDA for marketing. Unlike nutritional supple-
ments, which have no disease claim and are intended for healthy individuals, medical 
foods must make a disease claim and are intended for use in speciﬁc diseased popula-
tions. Disease claims must be supported by sound scientiﬁc evidence substantiating 
claims of successful nutritional management of the disease. All ingredients must be 
approved food additives or classiﬁed as Generally Recognized as Safe (GRAS). Reim-
bursement for medical foods is inconsistent, and varies by product and by health plan. 
Like medical foods in the US, FSMPs are intended for use only under medical supervi-
sion, but they must comply with EC regulations. There has been little to no economic 
research conducted with products in these categories. CONCLUSIONS: Medical foods 
and FSMPs can play a key role in the nutritional and metabolic support of patients 
with certain diseases and conditions, although their economic impact has not been 
studied.
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ALANYL-GLUTAMINE DIPEPTIDE (DIPEPTIVEN®) IN TOTAL 
PARENTERAL NUTRITION (TPN) THERAPY IN CRITICALLY ILL ITALIAN 
PATIENTS: A PHARMACOECONOMIC SIMULATION MODEL
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OBJECTIVES: Several clinical trials have demonstrated that the supplementation of 
Dipeptiven® in critically ill patients in Intensive Care Units (ICUs) is associated with 
better clinical outcomes, such as reduction of the infection rate, shortening of ICU           
and hospital lengths of stay (LOS), and a trend toward reduced mortality, when 
compared to standard TPN regimens. Aim of the study is the pharmacoeconomic 
evaluation of Dipeptiven vs. standard TPN in critically ill patients admitted to Italian 
ICUs. METHODS: The analysis is based on a Discrete Event Simulation model that 
incorporates: a) baseline outcomes rates from the 2007 GIVITI report (data from 200 
Italian ICUs and over 60,000 patients); b) Dipeptiven® efﬁcacy from systematic review 
and meta-analysis with a Bayesian Random-Effects model of the published clinical 
trials; c) national cost data in the perspective of the hospital from published sources. 
The simulated clinical outcomes are: death rate in ICU; infection rate in ICU; death         
rate in general ward; hospital LOS, divided into LOS pre-ICU, LOS in ICU, and LOS 
in ward (post-ICU). One-way and probabilistic sensitivity analyses were performed 
and the cost/effectiveness acceptability curve generated. RESULTS: Dipeptiven® 
results more effective and less costly than standard TPN reducing mortality rate 
(23.55% o 15.2% vs. 34.50% o 2.06%), infection rate (15.91% o 3.95% vs. 18.97% 
o 3.94%), overall hospital LOS (25.47 o 0.26 vs. 26.00   o 0.27 days) and total cost 
per patient (23,922 o 3,249 vs. 24,145   o a3,361). This indicates that treatment cost 
is completely offset by the reduction in ICU costs, and by antibiotic costs for the 
treatment of ICU-emergent infections. The cost/effectiveness acceptability curve shows      
that Dipepetiven® has an estimated 78% probability of resulting dominant and a 90% 
probability of resulting cost/effective if the decision maker is willing to pay up to 
a1500 to avoid one patient death.  CONCLUSIONS: Dipeptiven® is expected to 
averagely dominate standard TPN, as it results associated with better clinical and 
economic outcomes.
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THE PHARMACOECONOMIC ANALYSIS OF EXTEMPORAL MEDICINES 
USED FOR TREATMENT OF DISEASES AT CHILDREN IN UKRAINE
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OBJECTIVES: In Ukraine the medical products made in pharmacies by extempore 
use wide demand, is especial for treatment of children though the quantity of the 
pharmacies engaged in extemporal preparation every year decreases in connection 
with economic conditions, features of licensing of such activity in Ukraine. Use extem-
poral preparations with precisely picked up concentration corresponding by the 
medicinal form (the suppositories, a dosed out powder) allows to provide individual-
ized therapy of the child depending on age and weights of the body, accompanying 
diseases (for example a diabetes). METHODS: We have carried out the ÀÂÑ- analysis  
of extemporal medicines, which were prepared in pharmacies of Lviv city for 2008. 
RESULTS: Sample list of extemporal medicines has made 44 names for 2000 recipes. 
The dominating medicinal form solutions with precisely set concentration or features 
of their technological manufacturing make 45%. Also prepare for ointments (21%), 
dosed out powders (18%), suspensions (7%), mixtures (5%), suppositories (4%). 
Among medicinal forms are submitted a solution of clorhydrogenic acid with pepsi-
num, used for excitation of appetite at children, the recipe—Lassar paste for treatment 
of dermatitis at children. Such medicines are not made with a farmaceutical industry. 
CONCLUSIONS: We have deﬁned, that costs of extemporal medicines, in particular 
solutions makes 4–16 UAH (1 $  7.7 UAH), ointments 8–27 UAH, powders of 2–6 
UAN, suspension of 11–18 UAH. These extemporal medicines are economically 
 accessible to treatment for children in Ukraine.
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OBJECTIVES: Inadequate surgical hemostasis may lead to bleeding related complica-
tions and transfusion. The aim of this analysis was to examine the incidence and costs 
of bleeding complications and blood product transfusions for patients undergoing 
inpatient surgeries. METHODS: A retrospective analysis was conducted using Pre-
mier’s Perspective hospital database. Patients who had a procedure within a specialty 
of interest (i.e. cardiac, vascular, non-cardiac thoracic, solid organ, general, reproduc-
tive organ or knee/hip replacement) in 2006 or 2007 were identiﬁed via ICD-9 pro-
cedure codes. For each specialty, rate of bleeding complications (including bleeding 
event, re-operation to control for bleeding and blood product transfusions) were 
examined, and cost of hospitalizations and length of stay (LOS) were compared 
between surgeries with versus without complications. The incremental costs were 
based on a multivariate analysis adjusting for demographics (e.g., age, gender, geo-
graphic region), hospital characteristics (e.g., urban versus rural, bed size) and other 
baseline characteristics (e.g., comorbidities, admitting diagnosis, prior hospitaliza-
tion). RESULTS: A total of 647,918 cardiac, 725,624 vascular, 227,273 non-cardiac 
thoracic, 139,781 solid organ, 1,586,557 general, 1,032,762 reproductive organ and 
247,682 knee/hip replacement surgeries were identiﬁed. The rate of bleeding complica-
tion was highest for knee/hip replacement (29.8%), followed by vascular (27.1%), 
non-cardiac thoracic (26.5%), solid organ (23%), cardiac (11.7%), general (11.4%) 
and reproductive organ (3.3%). Incremental LOS associated with bleeding complica-
tions or transfusions was 11.5 days for non-cardiac thoracic, 10.5 days for solid organ, 
10.2 days for vascular, 9.6 days for general and 1.3 days for knee/hip replacement 
surgeries. The incremental cost per case of hospitalization associated with complica-
tion was highest for non-cardiac thoracic surgeries ($27,069), followed by vascular 
($26,272), cardiac ($20,261), solid organ ($18,420), general ($7,036), reproductive 
organ ($6,222) and knee/hip replacement ($3,246). CONCLUSIONS: This study 
characterizes the increased hospital LOS and cost associated with bleeding com-
plications and transfusions, and supports implementation of blood conservation 
strategies.
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A SYSTEMATIC REVIEW EVALUATING COST-EFFECTIVENESS  
OF ACUPUNCTURE
Kim SY, Lee H, Park HJ
Kyung Hee University, Seoul, South Korea
OBJECTIVES: Acupuncture is widely used for various diseases such as chronic low 
pain and osteoarthritis, but the cost-effectiveness of acupuncture has not been fully 
explored. The aim of this review is to summarize and assess randomized controlled 
trials (RCTs) of acupuncture for economic evaluation. METHODS: Total 5 electronic 
databases were searched up to May 2009 without language restrictions. The search 
terms used were “cost effectiveness”, “cost utility” and “cost beneﬁt” with “acupunc-
ture”. Studies presenting results of economic evaluation throughout prospective, 
 controlled studies for any medical condition were included. The quality of study was 
assessed. The main outcomes for health beneﬁt and cost were extracted and described. 
RESULTS: Thirteen RCTs that met the inclusion and exclusion criteria underwent a 
full-text review. Acupuncture with usual care was compared with usual care only in 
all studies. Nine studies were applied for pain condition including low back pain, 
headache, and dysmenorrhea. The reporting quality of the studies was poor for certain 
items. Nine studies described incremental cost-effectiveness ratio (ICER) or incremen-
tal cost per quality adjusted life year. Most studies suggested that additional acupunc-
ture treatment was cost-effective compare to the usual care for low back pain, 
headache, dysmenorrhea, osteoarthritis, angina pectoris, and allergic rhinitis. CON-
CLUSIONS: This systematic review showed the cost-effectiveness of additional acu-
puncture treatment, but including studies were very few and applied diseases were 
limited. Therefore the results could not be generalized due to diversity of disease and 
different status of each country. The more number of economic evaluations of 
 acupuncture are necessary to ﬁrm the evidence.
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OBJECTIVES: To implement, and assess the feasibility of an active surveillance model 
in community pharmacies to systematically detect adverse events (AEs) associated with 
the use of natural health products (NHPs) and NHP-drug interactions. METHODS: 
